Table 2 Background characteristics (efficacy analysis set)
n | Mean ± SD or % | ||
|---|---|---|---|
Age, y, mean ± SD | Total | 106 | 73.0 ± 8.6 |
Group 1 (30 mg without water)a | 32 | 77.0 ± 6.2 | |
Group 3 (30 mg with water)b | 32 | 76.7 ± 6.3 | |
Group 2 (60 mg without water)c | 21 | 67.7 ± 8.9 | |
Group 4 (60 mg with water)d | 21 | 66.9 ± 8.3 | |
Age (≥75 years old), % | Total | 52 | 49.1 |
Group 1 (30 mg without water)a | 21 | 65.6 | |
Group 3 (30 mg with water)b | 20 | 62.5 | |
Group 2 (60 mg without water)c | 6 | 28.6 | |
Group 4 (60 mg with water)d | 5 | 23.8 | |
Male, % | Total | 64 | 60.4 |
Group 1 (30 mg without water)a | 11 | 34.4 | |
Group 3 (30 mg with water)b | 12 | 37.5 | |
Group 2 (60 mg without water)c | 21 | 100.0 | |
Group 4 (60 mg with water)d | 20 | 95.2 | |
Height, cm, mean ± SD | Total | 79 | 161.64 ± 9.97 |
Group 1 (30 mg without water)a | 24 | 156.79 ± 8.43 | |
Group 3 (30 mg with water)b | 24 | 156.25 ± 7.19 | |
Group 2 (60 mg without water)c | 17 | 170.69 ± 7.93 | |
Group 4 (60 mg with water)d | 14 | 168.19 ± 7.22 | |
Body weight, kg, mean ± SD | Total | 106 | 61.12 ± 13.49 |
Group 1 (30 mg without water)a | 32 | 52.69 ± 7.38 | |
Group 3 (30 mg with water)b | 32 | 52.80 ± 6.71 | |
Group 2 (60 mg without water)c | 21 | 71.85 ± 11.13 | |
Group 4 (60 mg with water)d | 21 | 75.91 ± 10.09 | |
Prior cerebral infarction/transient ischemic attack, % | Total | 46 | 43.4 |
Group 1 (30 mg without water)a | 17 | 53.1 | |
Group 3 (30 mg with water)b | 14 | 43.8 | |
Group 2 (60 mg without water)c | 8 | 38.1 | |
Group 4 (60 mg with water)d | 7 | 33.3 |